Cargando…

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models

Delta-like-ligand 4 (DLL4) is a promising target to augment the effects of VEGF inhibitors. A simultaneous blockade of VEGF/VEGFR and DLL4/Notch signaling pathways leads to more potent anti-cancer effects by synergistic anti-angiogenic mechanisms in xenograft models. A bispecific antibody targeting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeom, Dong-Hoon, Lee, Yo-Seob, Ryu, Ilhwan, Lee, Sunju, Sung, Byungje, Lee, Han-Byul, Kim, Dongin, Ahn, Jin-Hyung, Ha, Eunsin, Choi, Yong-Soo, Lee, Sang Hoon, You, Weon-Kyoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796106/ https://www.ncbi.nlm.nih.gov/pubmed/33383646 http://dx.doi.org/10.3390/ijms22010241

Ejemplares similares

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
por: Kim, Da-Hyun, et al.
Publicado: (2020)

Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development
por: You, Weon-Kyoo, et al.
Publicado: (2023)

Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
por: Miles, Kiersten Marie, et al.
Publicado: (2014)

The Angiogenic Secretome in VEGF overexpressing Breast Cancer Xenografts
por: Dore-Savard, Louis, et al.
Publicado: (2016)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
por: You, Gihoon, et al.
Publicado: (2021)

Association of Dll4/Notch and HIF-1a -VEGF Signaling in the Angiogenesis of Missed Abortion
por: Fang, Yan, et al.
Publicado: (2013)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
por: Ko, Min Ji, et al.
Publicado: (2021)

Localization of VEGF to Vascular ECM Is an Important Aspect of Tumor Angiogenesis
por: You, Weon-Kyoo, et al.
Publicado: (2017)

Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier
por: Shin, Jung-Won, et al.
Publicado: (2022)

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer
por: Kim, Youjin, et al.
Publicado: (2019)

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
por: Geffers, Insa, et al.
Publicado: (2007)

Context-Dependent Functional Divergence of the Notch Ligands DLL1 and DLL4 In Vivo
por: Preuße, Kristina, et al.
Publicado: (2015)

Influence of Dll4 via HIF-1α-VEGF Signaling on the Angiogenesis of Choroidal Neovascularization under Hypoxic Conditions
por: Dong, Xiao, et al.
Publicado: (2011)

Preliminary Research of Main Components of Dll4/ Notch-VEGF Signaling Pathway Under High-Glucose Stimulation in vitro
por: Gao, Na, et al.
Publicado: (2022)

Dll4-Notch Signalling Blockade Synergizes Combined Ultrasound-Stimulated Microbubble and Radiation Therapy in Human Colon Cancer Xenografts
por: El Kaffas, Ahmed, et al.
Publicado: (2014)

Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine
por: Shimizu, Hiromichi, et al.
Publicado: (2014)

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
por: Paz-Ares, Luis, et al.
Publicado: (2023)

LDB2 regulates the expression of DLL4 through the formation of oligomeric complexes in endothelial cells
por: Choi, Hyun-Jung, et al.
Publicado: (2018)

Foxc Transcription Factors Directly Regulate Dll4 and Hey2 Expression by Interacting with the VEGF-Notch Signaling Pathways in Endothelial Cells
por: Hayashi, Hisaki, et al.
Publicado: (2008)

Altered ratios of pro‐ and anti‐angiogenic VEGF‐A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma
por: Ye, Xi, et al.
Publicado: (2016)

Polychlorinated biphenyls target Notch/Dll and VEGF R2 in the mouse placenta and human trophoblast cell lines for their anti-angiogenic effects
por: Kalkunte, Satyan, et al.
Publicado: (2017)

Xuan Bi Tong Yu Fang Promotes Angiogenesis via VEGF-Notch1/Dll4 Pathway in Myocardial Ischemic Rats
por: Li, Shuangdi, et al.
Publicado: (2020)

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009)

Normal Development in Mice Over-Expressing the Intracellular Domain of DLL1 Argues against Reverse Signaling by DLL1 In Vivo
por: Redeker, Christian, et al.
Publicado: (2013)

The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro
por: Tveriakhina, Lena, et al.
Publicado: (2018)

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
por: Lee, Eunhee, et al.
Publicado: (2023)

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models
por: Yu, Yanlan, et al.
Publicado: (2010)

Dll4-containing exosomes induce capillary sprout retraction in a 3D microenvironment
por: Sharghi-Namini, Soheila, et al.
Publicado: (2014)

Equine ovarian tissue xenografting: impacts of cooling, vitrification, and VEGF
por: Souza, Samara Silva, et al.
Publicado: (2021)

Establishment of a Cell Line (CNUH-HNSCC-1) Derived from an Advanced Laryngeal Squamous Cell Carcinoma
por: Lee, Dong-Hoon, et al.
Publicado: (2011)

Clinical implications of DLL4 expression in gastric cancer
por: Ishigami, Sumiya, et al.
Publicado: (2013)

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
por: Yao, James, et al.
Publicado: (2022)

Liposomal (64)Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts
por: Blocker, Stephanie J., et al.
Publicado: (2017)

Comparing efficacies of different treatment regimens in patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus using network meta-analysis
por: Lee, Seungji, et al.
Publicado: (2022)

Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
por: Register, Ames C., et al.
Publicado: (2021)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Cui, Xiaopei, et al.
Publicado: (2021)

The effect of 4-hexylresorcinol on xenograft degradation in a rat calvarial defect model
por: Kang, Yei-Jin, et al.
Publicado: (2016)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

YPL-001 Shows Various Beneficial Effects against Cigarette Smoke Extract-Induced Emphysema Formation: Anti-Inflammatory, Anti-Oxidative, and Anti-Apoptotic Effects
por: Lee, Kyoung-Hee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o9neqbke3cpqsmtc3022lflj4m